Program Description
The introduction of immune checkpoint inhibitors (ICIs) has altered the treatment landscape for patients with non-small cell lung cancer (NSCLC), offering additional therapy options beyond the first-line setting. Since the development of ICIs, the estimated 5-year survival rate for patients with NSCLC has increased from 25% to 50%. With numerous published and ongoing clinical trials and practice guideline updates surrounding use of ICIs in NSCLC, oncology practitioners and managed care professionals must be informed about recent changes in available and emerging treatment options. Yet despite increasing availability of ICIs and improved patient outcomes, the substantial cost of ICIs and their potential for significant toxicity are critical in cost-effectiveness evaluations. This article will review currently available and emerging investigational ICI agents for the frontline management of NSCLC, with specific attention to the impact of ICIs on quality-of-life outcomes, adverse effect management, and economic challenges associated with their use in patients with NSCLC.
Target audience: Managed Care Pharmacist, Oncology Pharmacist
Type of activity: Application
Release date: December 1, 2022
Expiration date: March 31, 2024
Time to complete activity: 2 hours
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Identify the rationale, value, and recommendations for PD-L1 testing in patients with non-small cell lung cancer (NSCLC) who are being considered for frontline treatment with immune checkpoint inhibitors (ICIs).
- Use the guideline recommendations and clinical data related to the frontline use of ICIs in the treatment selection for the management of advanced NSCLC.
- Explore best practices in optimizing biomarker testing and treatment selection associated with frontline use of ICIs in advanced NSCLC.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
